Oxonol & MGM-15 Guide: 7-OH, DEA Status and MIT

Oxonol is a commercial product name. MGM-15—dihydro-7-hydroxymitragynine—is a specific synthetic compound. For any product marketed as Oxonol, the active-ingredient declaration and supporting records define its chemistry—not the brand name.

What MGM-15 is

DEA identifies MGM-15 as a synthetic derivative related to 7-hydroxymitragynine. It is not mitragynine (MIT), and it is not ordinary Mitragyna speciosa leaf.

DEA temporarily placed MGM-15, mitragynine pseudoindoxyl (MGPI), and MGM-16 in Schedule I on August 26, 2026. The temporary order remains in effect through August 26, 2028 unless it is extended, replaced, or ended sooner.

Why the product name is not enough

Commercial names can persist while formulas, manufacturers, and legal status change. A current product record should name the active compound, amount basis, ingredients, manufacturer, lot or batch identifier, and whether the laboratory report covers the packaged product or only a source ingredient.

Descriptions of MGM-15 as a “legal 7-OH alternative” published before the August 2026 order no longer describe its current federal status.

How MIT differs

MIT means mitragynine, the principal named alkaloid in natural kratom leaf. Kratom Paradise's MIT tablets and extract powder are documented as mitragynine products; they do not contain or substitute for MGM-15.

Read the DEA temporary order · Review Kratom Paradise MIT records